OptiNose, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPTN research report →
Companywww.optinose.com
OptiNose, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
- CEO
- Ramy A. Mahmoud
- IPO
- 2017
- Employees
- 127
- HQ
- Yardley, PA, US
Price Chart
Valuation
- Market Cap
- $97.22M
- P/E
- -4.92
- P/S
- 2.38
- P/B
- -1.83
- EV/EBITDA
- -50.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.95%
- Op Margin
- -17.68%
- Net Margin
- -55.65%
- ROE
- 44.78%
- ROIC
- -10.79%
Growth & Income
- Revenue
- $78.23M · 10.20%
- Net Income
- $-21,541,000 · 39.29%
- EPS
- $-2.12 · -562.50%
- Op Income
- $-16,319,000
- FCF YoY
- -114.53%
Performance & Tape
- 52W High
- $20.02
- 52W Low
- $4.82
- 50D MA
- $8.91
- 200D MA
- $8.83
- Beta
- -0.89
- Avg Volume
- 119.12K
Get TickerSpark's AI analysis on OPTN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 21, 25 | Marino Michael F III | sell | 5,333 |
| May 21, 25 | Marino Michael F III | sell | 9,626 |
| May 21, 25 | Marino Michael F III | sell | 16,752 |
| May 21, 25 | Marino Michael F III | sell | 5,500 |
| May 21, 25 | Marino Michael F III | sell | 12,350 |
| May 21, 25 | Marino Michael F III | sell | 125,204 |
| May 21, 25 | Marino Michael F III | sell | 10,575 |
| May 21, 25 | Marino Michael F III | sell | 5,775 |
| May 21, 25 | Marino Michael F III | sell | 3,056 |
| May 21, 25 | Marino Michael F III | sell | 9,333 |
Our OPTN Coverage
We haven't published any research on OPTN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OPTN Report →